Sunovion Pharmaceuticals, born from the merging of Dainippon Sumitomo Pharma America, Incorporated (DSPA), and Sepracor, Incorporated, develops treatments for patients suffering from respiratory issues and central nervous system disorders. It is constantly developing new approaches, such as the drug LUNESTA (eszopiclone), which promotes healthy sleeping patterns, and Latuda (lurasidone HCI) for patients with symptoms of schizophrenia. The company’s devotion to nervous system issues is timely. For instance, the World Health Organization ranks schizophrenia as the sixth largest cause of disabilities globally.